Affordable Access

deepdyve-link
Publisher Website

Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer.

Authors
  • Dell'Oglio, Paolo1
  • Bishr, Mohamed2
  • Boehm, Katharina3
  • Trudeau, Vincent2
  • Larcher, Alessandro4
  • Tian, Zhe5
  • Sosa, Josè6
  • Moschini, Marco4
  • Saad, Fred7
  • Capitanio, Umberto4
  • Briganti, Alberto4
  • Graefen, Markus8
  • Montorsi, Francesco4
  • Karakiewicz, Pierre I2
  • 1 Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: [email protected] , (Canada)
  • 2 Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Urology, University of Montreal Health Center, Montreal, Canada. , (Canada)
  • 3 Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany. , (Canada)
  • 4 Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. , (Italy)
  • 5 Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada. , (Canada)
  • 6 Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada. , (Canada)
  • 7 Department of Urology, University of Montreal Health Center, Montreal, Canada. , (Canada)
  • 8 Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany. , (Germany)
Type
Published Article
Journal
European urology focus
Publication Date
Feb 11, 2017
Identifiers
DOI: 10.1016/j.euf.2017.01.017
PMID: 28753853
Source
Medline
Keywords
License
Unknown

Abstract

In this study, we looked at the survival patterns of octo- and nonagenarians treated with primary androgen deprivation therapy for organ-confined prostate cancer. We found that a small proportion of patients who received primary androgen deprivation therapy remain alive at 10-yr follow-up, and the leading cause of death was not attributable to prostate cancer.

Report this publication

Statistics

Seen <100 times